NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OBIO
Orchestra BioMed Holdings, Inc.
There isn't enough reported data to score OBIO yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
OBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OBIO PE Valuation
OBIO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect OBIO's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OBIO on earnings quality, reporting a profit while its opponent remains loss making.
OBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.73 | +$1.08 |
| Q2 2026 | -$0.83 | +$0.99 |
| Q1 2026 | -$0.95 | +$0.82 |
| Q4 2025 | -$1.11 | +$0.55 |
| Q3 2025 | -$1.81 | -$0.22 |
| Q2 2025 | -$1.82 | -$0.26 |
| Q1 2025 | -$1.77 | -$0.31 |
| Q4 2024 | -$1.66 | -$0.18 |
OBIO is still losing money, but far less than before: $0.73 per share over the past year, against $1.82 at its worst in mid-2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over OBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OBIO on profitability, with a higher operating margin.
OBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $91K | -89% |
| Q2 2026 | $88K | -89% |
| Q1 2026 | $110K | -87% |
| Q4 2025 | $30.9M | +12120% |
| Q3 2025 | $861K | -13% |
| Q2 2025 | $836K | +7.5% |
| Q1 2025 | $868K | +40% |
| Q4 2024 | $253K | -3.4% |
OBIO's revenue is growing: $91,000 last quarter, down 89% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25600% | -23241 points |
| Q2 2026 | -25405% | -23093 points |
| Q1 2026 | -20069% | -17889 points |
| Q4 2025 | 22% | +6614 points |
| Q3 2025 | -2359% | -704 points |
| Q2 2025 | -2312% | -145 points |
| Q1 2025 | -2180% | +146 points |
| Q4 2024 | -6592% | -1828 points |
OBIO's operating margin was −25600% last quarter, down 23241 points from the same quarter a year ago, near the bottom of its range since 2023.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
OBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.9M | -$5.1M |
| Q2 2026 | -$19.6M | -$4M |
| Q1 2026 | -$22.4M | -$5.6M |
| Q4 2025 | -$2.3M | +$11.3M |
| Q3 2025 | -$14.9M | -$1.1M |
| Q2 2025 | -$15.6M | -$5.2M |
| Q1 2025 | -$16.7M | -$3.6M |
| Q4 2024 | -$13.6M | -$2.7M |
OBIO has burned cash in almost every quarter: −$64M over the past year, against −$61M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +808K shares |
| 1 year | +24% | +12.4M shares |
| 3 years | +83% | +29.4M shares |
| 5 years | +304% | +48.6M shares |
| Available history | +216% | +44.2M shares |
OBIO has 65M diluted shares, up 24% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OBIO Net Leverage
OBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 77.1 | Neutral |
OBIO's weekly RSI is 65 (neutral) and its Stochastic is 77 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OBIO PE vs Healthcare Sector
OBIO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 5.5% above |
| 20 week MA | $5.13 | 20% above |
| 50 week MA | $4.55 | 35% above |
| 100 week MA | $4.09 | 50% above |
| 200 week MA | $6.09 | 1% above |
OBIO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $11.8 | -0.8% |
| 2021 | $11.8 | $9.83 | -17% |
| 2022 | $9.83 | $9.97 | +1.4% |
| 2023 | $9.97 | $9.13 | -8.4% |
| 2024 | $9.13 | $4.40 | -52% |
| 2025 | $4.40 | $4.32 | -1.8% |
| 2026 YTD | $4.32 | $6.15 | +42% |
OBIO has the edge over NVO on returns for 2026, with the stronger performance.